2 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
Follow Thyroid Gland Papillary Carcinoma: new trials by email Literature Review of Thyroid Gland Papillary Carcinoma trials Research Report on Thyroid Gland Papillary Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 21 | 2024-07-15 | 2026-02-02 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2020-02-10 | 2026-07-31 |
| Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Lenvatinib - Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma | Phase 2 | Terminated | Emory University | 4 | 2019-01-16 | 2022-11-10 |
Thyroid Cancer, Papillary (4) · Adenocarcinoma, Follicular (3) · Thyroid Neoplasms (2) · Carcinoma, Medullary (1) · Thyroid Carcinoma, Anaplastic (1)
Adenocarcinoma (4) · Adenocarcinoma, Papillary (4) · Carcinoma (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Head and Neck Neoplasms (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Thyroid Diseases (4) · Thyroid Neoplasms (2) · Carcinoma, Neuroendocrine (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Germ Cell and Embryonal (1)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · CTLA-4 Antigen (1) · Glycoprotein Hormones, alpha Subunit (1) · High-Energy Shock Waves (1) · Iodine-131 (1) · Ipilimumab (1) · Nivolumab (1) · Thyrotropin Alfa (1) · Vemurafenib (1) · X-Rays (1) · cabozantinib (1) · cobimetinib (1) · lenvatinib (1) · selpercatinib (1)
City of Hope Medical Center (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (4)
Bhavana Konda (1) · Mark Zafereo (1) · Sasan Fazeli (1) · Taofeek K. Owonikoko, MD, PhD (1)
P30CA033572 (1), UM1CA186712 (1)